Jagdish Shetty

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Robert L. Ferris, Robert I. Haddad, Caroline Even et al. · Annals of Oncology · 2020 · 365 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Lisa Licitra, Robert I. Haddad, Caroline Even et al. · Journal of Clinical Oncology · 2019 · 39 citations

Medicine, Oncology, Pharmacology +16

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Sara M. Tolaney, Zefei Jiang, Qingyuan Zhang et al. · New England Journal of Medicine · 2025 · 37 citations

Medicine, Oncology, Pharmacology +16

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sophie Wildsmith, Weimin Li, Song Wu et al. · Clinical Cancer Research · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Sara M. Tolaney, Zefei Jiang, Qingyuan Zhang et al. · Journal of Clinical Oncology · 2025 · 30 citations

Medicine, Oncology, Pharmacology +17